Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Victoria Richon
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Anatomy
Living Beings
Physiology
Disorders
Phenomena
Sign-in to see full Profile
Network (preview)
54
Marks, Paul
42
Rifkind, Richard
9
Breslow, Ronald
6
Butler, Lisa
6
Cordon-Cardo, Carlos
6
Kelly, Kevin
6
Scher, Howard
5
Secrist, Paul
5
Ngo, Lang
5
LaQuaglia, Michael
5
Zhou, Xianbo
4
Kiyokawa, Hiroaki
4
Glick, Richard
4
Drobnjak, Marija
4
Chiao, Judy
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Victoria Richon (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2008: Lee Anita Y H; Paweletz Cloud P; Pollock Roy M; Settlage Robert E; Cruz Jonathan C; Secrist J Paul; Miller Thomas A; Stanton Matthew G; Kral Astrid M; Ozerova Nicole D S; Meng Fanyu; Yates Nathan A; Richon Victoria; Hendrickson Ronald C
Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry.
Journal of proteome research 2008;7(12):5177-86.
-
2008: Zhan Yanai; Ginanni Nicole; Tota Michael R; Wu Margaret; Bays Nathan W; Richon Victoria M; Kohl Nancy E; Bachman Eric S; Strack Peter R; Krauss Stefan
Control of cell growth and survival by enzymes of the fatty acid synthesis pathway in HCT-116 colon cancer cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(18):5735-42.
-
2008: Richon Victoria M
A new path to the cancer epigenome.
Nature biotechnology 2008;26(6):655-6.
-
2008: Fantin Valeria R; Loboda Andrey; Paweletz Cloud P; Hendrickson Ronald C; Pierce Jacqueline W; Roth Jennifer A; Li Lixia; Gooden Frank; Korenchuk Susan; Hou Xiaoli S; Harrington Elizabeth A; Randolph Sophia; Reilly John F; Ware Christopher M; Kadin Marshall E; Frankel Stanley R; Richon Victoria M
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma.
Cancer research 2008;68(10):3785-94.
-
2008: Garcia-Manero Guillermo; Yang Hui; Bueso-Ramos Carlos; Ferrajoli Alessandra; Cortes Jorge; Wierda William G; Faderl Stefan; Koller Charles; Morris Gail; Rosner Gary; Loboda Andrey; Fantin Valeria R; Randolph Sophia S; Hardwick James S; Reilly John F; Chen Cong; Ricker Justin L; Secrist J Paul; Richon Victoria M; Frankel Stanley R; Kantarjian Hagop M
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Blood 2008;111(3):1060-6.
-
2007: Fantin Valeria R; Richon Victoria M
Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(24):7237-42.
-
2007: Belvedere Sandro; Witter David J; Yan Jiaming; Secrist J Paul; Richon Victoria; Miller Thomas A
Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors.
Bioorganic & medicinal chemistry letters 2007;17(14):3969-71.
-
2007: Lindemann R K; Newbold A; Whitecross K F; Cluse L A; Frew A J; Ellis L; Williams S; Wiegmans A P; Dear A E; Scott C L; Pellegrini M; Wei A; Richon V M; Marks Paul A; Lowe S W; Smyth M J; Johnstone R W
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(19):8071-6.
-
2007: Marrocco Deborah L; Tilley Wayne D; Bianco-Miotto Tina; Evdokiou Andreas; Scher Howard I; Rifkind Richard A; Marks Paul A; Richon Victoria M; Butler Lisa M
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Molecular cancer therapeutics 2007;6(1):51-60.
-
2007: Duvic Madeleine; Talpur Rakshandra; Ni Xiao; Zhang Chunlei; Hazarika Parul; Kelly Cecilia; Chiao Judy H; Reilly John F; Ricker Justin L; Richon Victoria M; Frankel Stanley R
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
Blood 2007;109(1):31-9.
-
2006: Munshi Anupama; Tanaka Toshimitsu; Hobbs Marvette L; Tucker Susan L; Richon Victoria M; Meyn Raymond E
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci.
Molecular cancer therapeutics 2006;5(8):1967-74.
-
2006: Sanchez-Gonzalez Blanca; Yang Hui; Bueso-Ramos Carlos; Hoshino Koyu; Quintas-Cardama Alfonso; Richon Victoria M; Garcia-Manero Guillermo
Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor.
Blood 2006;108(4):1174-82.
-
2006: O'Connor Owen A; Heaney Mark L; Schwartz Lawrence; Richardson Stacie; Willim Robert; MacGregor-Cortelli Barbara; Curly Tracey; Moskowitz Craig; Portlock Carol; Horwitz Steven; Zelenetz Andrew D; Frankel Stanley; Richon Victoria; Marks Paul; Kelly William K
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(1):166-73.
-
2005: Zhang Chunlei; Richon Victoria; Ni Xiao; Talpur Rakhshandra; Duvic Madeleine
Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
The Journal of investigative dermatology 2005;125(5):1045-52.
-
2005: Kelly William Kevin; O'Connor Owen A; Krug Lee M; Chiao Judy H; Heaney Mark; Curley Tracy; MacGregore-Cortelli Barbara; Tong William; Secrist J Paul; Schwartz Lawrence; Richardson Stacy; Chu Elaina; Olgac Semra; Marks Paul A; Scher Howard; Richon Victoria M
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(17):3923-31.
-
2005: Mitsiades Constantine S; Poulaki Vassiliki; McMullan Ciaran; Negri Joseph; Fanourakis Galinos; Goudopoulou Athina; Richon Victoria M; Marks Paul A; Mitsiades Nicholas
Novel histone deacetylase inhibitors in the treatment of thyroid cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(10):3958-65.
-
2005: Peart Melissa J; Smyth Gordon K; van Laar Ryan K; Bowtell David D; Richon Victoria M; Marks Paul A; Holloway Andrew J; Johnstone Ricky W
Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(10):3697-702.
-
2004: Reilly Christopher M; Mishra Nilamadhab; Miller Julie M; Joshi Dimple; Ruiz Phillip; Richon Victoria M; Marks Paul A; Gilkeson Gary S
Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid.
Journal of immunology (Baltimore, Md. : 1950) 2004;173(6):4171-8.
-
2004: Marchion Douglas C; Bicaku Elona; Daud Adil I; Richon Victoria; Sullivan Daniel M; Munster Pamela N
Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
Journal of cellular biochemistry 2004;92(2):223-37.
-
2004: Gui C-Y; Ngo L; Xu W S; Richon V M; Marks P A
Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(5):1241-6.
-
2004: Mitsiades Constantine S; Mitsiades Nicholas S; McMullan Ciaran J; Poulaki Vassiliki; Shringarpure Reshma; Hideshima Teru; Akiyama Masaharu; Chauhan Dharminder; Munshi Nikhil; Gu Xuesong; Bailey Charles; Joseph Marie; Libermann Towia A; Richon Victoria M; Marks Paul A; Anderson Kenneth C
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(2):540-5.
-
2004: Marks Paul A; Richon Victoria M; Miller Thomas; Kelly William Kevin
Histone deacetylase inhibitors.
Advances in cancer research 2004;91():137-68.
-
2004: Marks Paul A; Richon Victoria M; Kelly Wm Kevin; Chiao Judy H; Miller Thomas
Histone deacetylase inhibitors: development as cancer therapy.
Novartis Foundation symposium 2004;259():269-81; discussion 281-8.
-
2004: Richon Victoria M; Zhou Xianbo; Secrist J Paul; Cordon-Cardo Carlos; Kelly W Kevin; Drobnjak Marija; Marks Paul A
Histone deacetylase inhibitors: assays to assess effectiveness in vitro and in vivo.
Methods in enzymology 2004;376():199-205.
-
2003: Secrist J Paul; Zhou Xianbo; Richon Victoria M
HDAC inhibitors for the treatment of cancer.
Current opinion in investigational drugs (London, England : 2000) 2003;4(12):1422-7.
-
2003: Kutko Martha C; Glick Richard D; Butler Lisa M; Coffey Dennis C; Rifkind Richard A; Marks Paul A; Richon Victoria M; LaQuaglia Michael P
Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5749-55.
-
2003: Kelly Wm Kevin; Richon Victoria M; O'Connor Owen; Curley Tracy; MacGregor-Curtelli Barbara; Tong William; Klang Mark; Schwartz Lawrence; Richardson Stacie; Rosa Eddie; Drobnjak Marija; Cordon-Cordo Carlos; Chiao Judy H; Rifkind Richard; Marks Paul A; Scher Howard
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3578-88.
-
2003: Marks Paul A; Miller Thomas; Richon Victoria M
Histone deacetylases.
Current opinion in pharmacology 2003;3(4):344-51.
-
2003: Mitsiades Nicholas; Mitsiades Constantine S; Richardson Paul G; McMullan Ciaran; Poulaki Vassiliki; Fanourakis Galinos; Schlossman Robert; Chauhan Dharminder; Munshi Nikhil C; Hideshima Teru; Richon Victoria M; Marks Paul A; Anderson Kenneth C
Molecular sequelae of histone deacetylase inhibition in human malignant B cells.
Blood 2003;101(10):4055-62.
-
2003: Hockly Emma; Richon Victoria M; Woodman Benjamin; Smith Donna L; Zhou Xianbo; Rosa Eddie; Sathasivam Kirupa; Ghazi-Noori Shabnam; Mahal Amarbirpal; Lowden Philip A S; Steffan Joan S; Marsh J Lawrence; Thompson Leslie M; Lewis Cathryn M; Marks Paul A; Bates Gillian P
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(4):2041-6.
-
2002: Butler Lisa M; Zhou Xianbo; Xu Wei-Sheng; Scher Howard I; Rifkind Richard A; Marks Paul A; Richon Victoria M
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(18):11700-5.
-
2002: Cohen Leonard A; Marks Paul A; Rifkind Richard A; Amin Shantu; Desai Dhimant; Pittman Brian; Richon Victoria M
Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors.
Anticancer research 2002;22(3):1497-504.
-
2002: Richon Victoria M; O'Brien James P
Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(3):662-4.
-
2001: Marks P; Rifkind R A; Richon V M; Breslow R; Miller T; Kelly W K
Histone deacetylases and cancer: causes and therapies.
Nature reviews. Cancer 2001;1(3):194-202.
-
2001: Munster P N; Troso-Sandoval T; Rosen N; Rifkind R; Marks P A; Richon V M
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
Cancer research 2001;61(23):8492-7.
-
2001: He L Z; Tolentino T; Grayson P; Zhong S; Warrell R P; Rifkind R A; Marks P A; Richon V M; Pandolfi P P
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.
The Journal of clinical investigation 2001;108(9):1321-30.
-
2001: Marks P A; Richon V M; Breslow R; Rifkind R A
Histone deacetylase inhibitors as new cancer drugs.
Current opinion in oncology 2001;13(6):477-83.
-
2001: Zhou X; Marks P A; Rifkind R A; Richon V M
Cloning and characterization of a histone deacetylase, HDAC9.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(19):10572-7.
-
2001: Coffey D C; Kutko M C; Glick R D; Butler L M; Heller G; Rifkind R A; Marks P A; Richon V M; La Quaglia M P
The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid.
Cancer research 2001;61(9):3591-4.
-
2001: Butler L M; Webb Y; Agus D B; Higgins B; Tolentino T R; Kutko M C; LaQuaglia M P; Drobnjak M; Cordon-Cardo C; Scher H I; Breslow R; Richon V M; Rifkind R A; Marks P A
Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(4):962-70.
-
2001: Marks P A; Rifkind R A; Richon V M; Breslow R
Inhibitors of histone deacetylase are potentially effective anticancer agents.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(4):759-60.
-
2001: Richon V M; Zhou X; Rifkind R A; Marks P A
Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.
Blood cells, molecules & diseases 2001;27(1):260-4.
-
2000: Zhou X; Richon V M; Wang A H; Yang X J; Rifkind R A; Marks P A
Histone deacetylase 4 associates with extracellular signal-regulated kinases 1 and 2, and its cellular localization is regulated by oncogenic Ras.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(26):14329-33.
-
2000: Coffey D C; Kutko M C; Glick R D; Swendeman S L; Butler L; Rifkind R; Marks P A; Richon V M; LaQuaglia M P
Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro.
Medical and pediatric oncology 2000;35(6):577-81.
-
2000: Butler L M; Agus D B; Scher H I; Higgins B; Rose A; Cordon-Cardo C; Thaler H T; Rifkind R A; Marks P A; Richon V M
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
Cancer research 2000;60(18):5165-70.
-
2000: Richon V M; Sandhoff T W; Rifkind R A; Marks P A
Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(18):10014-9.
-
2000: Marks P A; Richon V M; Rifkind R A
Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.
Journal of the National Cancer Institute 2000;92(15):1210-6.
-
2000: Zhou X; Richon V M; Rifkind R A; Marks P A
Identification of a transcriptional repressor related to the noncatalytic domain of histone deacetylases 4 and 5.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(3):1056-61.
-
1999: Cohen L A; Amin S; Marks P A; Rifkind R A; Desai D; Richon V M
Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA).
Anticancer research 1999;19(6B):4999-5005.
-
1999: Finnin M S; Donigian J R; Cohen A; Richon V M; Rifkind R A; Marks P A; Breslow R; Pavletich N P
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.
Nature 1999;401(6749):188-93.
-
1999: Glick R D; Swendeman S L; Coffey D C; Rifkind R A; Marks P A; Richon V M; La Quaglia M P
Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma.
Cancer research 1999;59(17):4392-9.
-
1999: Zhou X; Richon V M; Ngo L; Rifkind R A; Marks P A
Cloning of the cDNA encoding phenylalanyl tRNA synthetase regulatory alpha-subunit-like protein whose expression is down-regulated during differentiation.
Gene 1999;233(1-2):13-9.
-
1999: Rabbani F; Richon V M; Orlow I; Lu M L; Drobnjak M; Dudas M; Charytonowicz E; Dalbagni G; Cordon-Cardo C
Prognostic significance of transcription factor E2F-1 in bladder cancer: genotypic and phenotypic characterization.
Journal of the National Cancer Institute 1999;91(10):874-81.
-
1999: Webb Y; Zhou X; Ngo L; Cornish V; Stahl J; Erdjument-Bromage H; Tempst P; Rifkind R A; Marks P A; Breslow R; Richon V M
Photoaffinity labeling and mass spectrometry identify ribosomal protein S3 as a potential target for hybrid polar cytodifferentiation agents.
The Journal of biological chemistry 1999;274(20):14280-7.
-
1999: Marks P A; Richon V M; Breslow R; Rifkind R A
Hybrid polar inducers of transformed cell differentiation/apoptosis. From the cell to the clinic.
Comptes rendus de l'Académie des sciences. Série III, Sciences de la vie 1999;322(2-3):161-5.
-
1998: Warrell R P; He L Z; Richon V; Calleja E; Pandolfi P P
Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.
Journal of the National Cancer Institute 1998;90(21):1621-5.
-
1998: Lyle R E; Richon V M; McGehee R E
TNFalpha disrupts mitotic clonal expansion and regulation of retinoblastoma proteins p130 and p107 during 3T3-L1 adipocyte differentiation.
Biochemical and biophysical research communications 1998;247(2):373-8.
-
1998: Richon V M; Emiliani S; Verdin E; Webb Y; Breslow R; Rifkind R A; Marks P A
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(6):3003-7.
-
1998: Siegel D S; Zhang X; Feinman R; Teitz T; Zelenetz A; Richon V M; Rifkind R A; Marks P A; Michaeli J
Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(1):162-6.
-
1997: Richon V M; Russo P; Venta-Perez G; Cordon-Cardo C; Rifkind R A; Marks P A
Two cytodifferentiation agent-induced pathways, differentiation and apoptosis, are distinguished by the expression of human papillomavirus 16 E7 in human bladder carcinoma cells.
Cancer research 1997;57(13):2789-98.
-
1997: Richon V M; Lyle R E; McGehee R E
Regulation and expression of retinoblastoma proteins p107 and p130 during 3T3-L1 adipocyte differentiation.
The Journal of biological chemistry 1997;272(15):10117-24.
-
1996: Marks P A; Richon V M; Rifkind R A
Induced differentiation of cancer cells: second generation potent hybrid polar compounds target cell cycle regulators.
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 1996;5 Suppl 2():75-7.
-
1996: Richon V M; Webb Y; Merger R; Sheppard T; Jursic B; Ngo L; Civoli F; Breslow R; Rifkind R A; Marks P A
Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(12):5705-8.
-
1996: Richon V M; Venta-Perez G
Changes in E2F DNA-binding activity during induced erythroid differentiation.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1996;7(1):31-42.
-
1996: Marks P A; Richon V M; Rifkind R A
Cell cycle regulatory proteins are targets for induced differentiation of transformed cells: Molecular and clinical studies employing hybrid polar compounds.
International journal of hematology 1996;63(1):1-17.
-
1996: Rifkind R A; Richon V M; Marks P A
Induced differentiation, the cell cycle, and the treatment of cancer.
Pharmacology & therapeutics 1996;69(2):97-102.
-
1994: Kiyokawa H; Richon V M; Rifkind R A; Marks P A
Suppression of cyclin-dependent kinase 4 during induced differentiation of erythroleukemia cells.
Molecular and cellular biology 1994;14(11):7195-203.
-
1994: Marks P A; Richon V M; Kiyokawa H; Rifkind R A
Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(22):10251-4.
-
1994: Cordon-Cardo C; Richon V M
Expression of the retinoblastoma protein is regulated in normal human tissues.
The American journal of pathology 1994;144(3):500-10.
-
1993: Leng L; Yu F; Dong L; Busquets X; Osada S; Richon V M; Marks P A; Rifkind R A
Differential modulation of protein kinase C isoforms in erythroleukemia during induced differentiation.
Cancer research 1993;53(22):5554-8.
-
1993: Kiyokawa H; Richon V M; Venta-Perez G; Rifkind R A; Marks P A
Hexamethylenebisacetamide-induced erythroleukemia cell differentiation involves modulation of events required for cell cycle progression through G1.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(14):6746-50.
-
1992: Richon V M; Rifkind R A; Marks P A
Expression and phosphorylation of the retinoblastoma protein during induced differentiation of murine erythroleukemia cells.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1992;3(7):413-20.
-
1991: Richon V M; Weich N; Leng L; Kiyokawa H; Ngo L; Rifkind R A; Marks P A
Characteristics of erythroleukemia cells selected for vincristine resistance that have accelerated inducer-mediated differentiation.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(5):1666-70.
-
1990: Michaeli J; Lebedev Y B; Richon V M; Chen Z X; Marks P A; Rifkind R A
Conversion of differentiation inducer resistance to differentiation inducer sensitivity in erythroleukemia cells.
Molecular and cellular biology 1990;10(7):3535-40.
-
1989: Richon V M; Ramsay R G; Rifkind R A; Marks P A
Modulation of the c-myb, c-myc and p53 mRNA and protein levels during induced murine erythroleukemia cell differentiation.
Oncogene 1989;4(2):165-73.
-
1989: Marks P A; Michaeli J; Jackson J; Richon V M; Rifkind R A
Induced differentiation of murine erythroleukemia cells (MELC) by polar compounds: marked increased sensitivity of vincristine resistant MELC.
Progress in clinical and biological research 1989;316B():171-81.
-
1988: Mydlo J H; Bulbul M A; Richon V M; Heston W D; Fair W R
Heparin-binding growth factor isolated from human prostatic extracts.
The Prostate 1988;12(4):343-55.
Sign-in to see more
